Compare ABLV & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | INCR |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | China | Israel |
| Employees | 164 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 47.4M |
| IPO Year | N/A | 2021 |
| Metric | ABLV | INCR |
|---|---|---|
| Price | $1.11 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.5K | 32.9K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.68 |
| 52 Week High | $1.77 | $1.77 |
| Indicator | ABLV | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 52.58 |
| Support Level | $0.83 | $0.72 |
| Resistance Level | $1.25 | $1.23 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 65.45 | 27.65 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.